Cargando…
Recapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab
Autores principales: | Jayasekera, Prativa S., Parslew, Richard A., Al-Sharqi, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982921/ https://www.ncbi.nlm.nih.gov/pubmed/27547809 http://dx.doi.org/10.1016/j.jdcr.2016.05.004 |
Ejemplares similares
-
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
por: van der Schoot, Lara S., et al.
Publicado: (2022) -
Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011) -
Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009) -
Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015) -
Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
por: Olabi, Bayanne, et al.
Publicado: (2020)